Health Condition 1: H318- Other specified disorders of choroid
Conditions
Interventions
Intervention1: Oral Eplerenone, Intravitreal Aflibercept: Oral Eplerenone 25mg PO OD for 7 days followed by 50mg PO OD, Intravitreal Aflibercept 2mg 0.05ml monthly injection for 3 months
Control Inter
Sponsors
Dept of Ophthalmology RPC AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: 1. ICGA diagnosed PCV, that is, presence of early subretinal focal ICGA hyper�uorescence (appearing within the �rst 6 minutes after injection of indocyanine green) and in addition, at least one of the following angiographic or clinical criteria: (i) Association with a BVN (ii) Presence of pulsatile polyp (iii) Nodular appearance when viewed stereoscopically (iv) Presence of hypo�uorescent halo (in �rst 6 minutes), (v) Orange subretinal nodules in stereoscopic colour fundus photograph(polyp corresponding to ICGA lesions), or 2. Patient willing to be included in the study 3. BCVA better than 6/60
Exclusion criteria
Exclusion criteria: 1. Simultaneous RPE Tear, Retinal detachment, macular hole or uncontrolled glaucoma 2. Previous intraocular surgery except uncomplicated cataract extraction with intraocular lens implantation within 60 days before screening visit 3. Baseline serum potassium concentration of more than 5 Mmol/Lit 4. Pregnancy or planning to conceive 5. BP > 140/90 mmHg 6. Submacular haemorrhage >4 disc diameter
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in Best Corrected Visual AcuityTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete regression of polyp, Decrement in Choroidal thicknessTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Vipul Singh
All India Institute of Medical Sciences (AIIMS), New Delhi
Outcome results
None listed